Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
Design a Two-Stage Process for Using Rwe to Support Labeling Expansions for Effectiveness Claims That Is Aligned with R… is a federal Unrestricted award for Fda Office Of Acq Grant Svcs held by Brigham & Womens Hospital Inc. Estimated value $2.7M ($2.7M obligated). Current period of performance ends Jun 27, 2027. Last award drew 165 bidders. Place of performance: SILVER SPRING MD.
Design a two-stage process for using rwe to support labeling expansions for effectiveness claims that is aligned with regulatory requirements/demonstrate and empirically test the process with historical and ongoing rcts for supplemental indications/. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Jun 27, 2027 (253 days remaining). Agencies typically plan 12–18 months ahead — at 8.3 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75F40122C00154? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordBrigham & Womens Hospital Inc — $20.7M obligated across 79 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40122C00154?
75F40122C00154 (Design a two-stage process for using) is a Fda Office Of Acq Grant Svcs award with a potential value of $2.7M, currently held by Brigham & Womens Hospital Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40122C00154?
Fda Office Of Acq Grant Svcs awarded 75F40122C00154 to Brigham & Womens Hospital Inc (potential $2.7M).
Who is the incumbent on 75F40122C00154?
Brigham & Womens Hospital Inc is the incumbent with $20.7M across 79 related awards in SCOUT’s public footprint. The current period of performance ends Jun 27, 2027.
When does Brigham & Womens Hospital Inc’s 75F40122C00154 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 27, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75F40122C00154? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.